Shupeng Wen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shupeng Wen has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Jianmin Luo
Department of Hematology, the Second Hospital of Hebei Medical University, Key Laboratory of Hematology, Shijiazhuang, China
2 shared publications - Fu-Xu Wang
The Second Hospital of Hebei Medical University
1 shared publication - Hang Li
Department of Histology and Embryology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China
1 shared publication Lin Yang
Department of Hematology, the Second Hospital of Hebei Medical University, Key Laboratory of Hematology, Shijiazhuang, China
1 shared publication- Lina Xing
Department of Hematology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang, 050000, Hebei, China
1 shared publication - Na Kuang
Hebei Senlangbio Technology Co., LTD, Shijiazhuang, 050000, Hebei, China
1 shared publication
Latest Publications
- Open Access
- 4 November 2026
- Published by Springer Nature in Annals of Hematology
Marrow remodeling is associated with adverse co-mutational complexity in CALR-mutated primary myelofibrosis: a clinicopathologic study
- 4 November 2026
- Published by Springer Nature in Annals of Hematology
Open AccessMarrow remodeling is associated with adverse co-mutational complexity in CALR-mutated primary myelofibrosis: a clinicopathologic study
- Open Access
- 20 November 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1143
CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report
Adults with relapsed acute lymphoblastic leukemia (ALL) have a poor prognosis, especially in patients who relapsed within 6 months of complete remission 1 (CR1). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the treatment of choice. However, this can only be considered after complete remission 2 (CR2) is achieved. Therefore, bridging treatment is urgently needed. In the present study, we report a relapsed adult B-cell ALL case that achieved CR2 after treatment with CD19-directed chimeric antigen receptor (CAR)-modified T cell (CAR-T) therapy. After subsequent allo-HSCT, the patient acquired 21 months of disease-free survival. The present results confirm that both CAR-T and allo-HSCT are effective for treating refractory or relapsed B-ALL. However, a novel sequential treatment strategy with these two therapeutic methods may achieve longer disease-free survival time.
- 20 November 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1143
Open AccessCAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report
Adults with relapsed acute lymphoblastic leukemia (ALL) have a poor prognosis, especially in patients who relapsed within 6 months of complete remission 1 (CR1). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the treatment of choice. However, this can only be considered after complete remission 2 (CR2) is achieved. Therefore, bridging treatment is urgently needed. In the present study, we report a relapsed adult B-cell ALL case that achieved CR2 after treatment with CD19-directed chimeric antigen receptor (CAR)-modified T cell (CAR-T) therapy. After subsequent allo-HSCT, the patient acquired 21 months of disease-free survival. The present results confirm that both CAR-T and allo-HSCT are effective for treating refractory or relapsed B-ALL. However, a novel sequential treatment strategy with these two therapeutic methods may achieve longer disease-free survival time.